Stocktoria
Neumora Therapeutics, Inc. NMRA
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2023-09-15
Chart by TradingView
1/9
Piotroski F — financial health
-22.01
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials & ratios (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Financials | ||||
| Operating income | -$241.2M | -$263.5M | -$252.1M | -$135.9M |
| Net income | -$236.9M | -$243.8M | -$235.9M | -$130.9M |
| Operating cash flow | -$206.4M | -$182.9M | -$163.3M | -$114.9M |
| Free cash flow | — | — | -$163.4M | -$115.4M |
| Total assets | $191.0M | $317.0M | $496.2M | $426.2M |
| Total liabilities | $87.2M | $29.9M | $27.1M | $29.4M |
| Shareholders' equity | $103.9M | $287.1M | $469.1M | -$446.9M |
| Ratios | ||||
| Return on assets | -124.0% | -76.9% | -47.5% | -30.7% |
| Return on equity | -228.1% | -84.9% | -50.3% | 29.3% |
| Debt / equity | 0.52× | 0.00× | — | — |
| Current ratio | 5.87 | 10.51 | 19.05 | 16.37 |
Notable holders (13F)
| Investor | Shares | Value |
|---|---|---|
| RENAISSANCE TECHNOLOGIES LLC | 1,388,998 | $2.7M |
| Point72 Asset Management, L.P. | 602,403 | $1.2M |
Why these scores methodology →
Piotroski F-score: 1/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -22.01 (distress)
- Working capital / assets 0.827
- Retained earnings / assets -6.198
- EBIT / assets -1.262
- Equity / liabilities 1.192
Sector peers
VFS · TM · HMC · SONY · AAPL · XOM · all Manufacturing →
Source: SEC EDGAR filings · CIK 0001885522 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.